[{"data":1,"prerenderedAt":48},["ShallowReactive",2],{"q-nurse-111-2-basic-medicine-040":3},{"subject":4,"subjectSlug":5,"subjectFullName":6,"question":7,"related":24},"基礎醫學","basic-medicine","基礎醫學(包括解剖學、生理學、病理學、藥理學、微生物學與免疫學)",{"id":8,"webId":9,"year":10,"session":11,"subject":4,"number":12,"stem":13,"options":14,"answer":19,"answerNote":20,"images":21,"explanation":22,"freq":23},"nurse-111-2-基礎醫學-040","nurse-111-2-basic-medicine-040",111,2,40,"Imatinib 是慢性骨髓性白血病（chronic myeloid leukemia）的標靶療法用藥，下列何者為其作用機轉？",{"A":15,"B":16,"C":17,"D":18},"抑制 BCR-ABL","抑制 EGF receptor","抑制 HER2","抑制 c-KIT","A",null,[],"本題考點為標靶藥 Imatinib 的作用機轉。慢性骨髓性白血病（CML）帶有費城染色體 t(9;22)，產生 BCR-ABL 融合基因，是持續活化的酪胺酸激酶；Imatinib 為酪胺酸激酶抑制劑，專一抑制 BCR-ABL，阻斷異常增生訊號，故選 A。(B)EGFR 為 gefitinib 等肺癌用藥標的。(C)HER2 為 trastuzumab（乳癌）標的。(D)c-KIT 雖亦可被 imatinib 抑制（用於胃腸道基質瘤），但 CML 的定義性標的為 BCR-ABL，故選 A。",1,[25,29,32,36,40,44],{"webId":26,"stem":27,"number":23,"year":28,"session":23},"nurse-106-1-basic-medicine-001","下列有關表皮的敘述，何者正確？",106,{"webId":30,"stem":31,"number":11,"year":28,"session":23},"nurse-106-1-basic-medicine-002","下列何者在組織學特徵上可區分為絲球帶（zona glomerulosa）、束狀帶（zona fasciculata）、網狀帶（zona reticularis）？",{"webId":33,"stem":34,"number":35,"year":28,"session":23},"nurse-106-1-basic-medicine-003","顴弓（zygomatic arch）是由顴骨與下列何者共同組成？",3,{"webId":37,"stem":38,"number":39,"year":28,"session":23},"nurse-106-1-basic-medicine-004","下列何者參與形成踝關節？",4,{"webId":41,"stem":42,"number":43,"year":28,"session":23},"nurse-106-1-basic-medicine-005","下列何者是維持背部直立最重要的肌肉？",5,{"webId":45,"stem":46,"number":47,"year":28,"session":23},"nurse-106-1-basic-medicine-006","行走於前臂的內側，並與上臂深層的靜脈會合成腋靜脈的是那一條血管？",6,1783840769182]